Treatment of mild headache in disabled migraine sufferers: Results of the spectrum study

R. K. Cady, Richard B. Lipton, Charles B. Hall, W. F. Stewart, S. O'Quinn, D. Gutterman

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.

Original languageEnglish (US)
Pages (from-to)792-797
Number of pages6
JournalHeadache
Volume40
Issue number10
DOIs
StatePublished - 2000

Fingerprint

Migraine Disorders
Headache
Pain
Sumatriptan
Placebos
Therapeutics
Recurrence
Drug-Related Side Effects and Adverse Reactions
Tablets
Safety
Pain-Free

Keywords

  • Disability
  • Migraine
  • Mild
  • Spectrum
  • Sumatriptan

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Treatment of mild headache in disabled migraine sufferers : Results of the spectrum study. / Cady, R. K.; Lipton, Richard B.; Hall, Charles B.; Stewart, W. F.; O'Quinn, S.; Gutterman, D.

In: Headache, Vol. 40, No. 10, 2000, p. 792-797.

Research output: Contribution to journalArticle

Cady, R. K. ; Lipton, Richard B. ; Hall, Charles B. ; Stewart, W. F. ; O'Quinn, S. ; Gutterman, D. / Treatment of mild headache in disabled migraine sufferers : Results of the spectrum study. In: Headache. 2000 ; Vol. 40, No. 10. pp. 792-797.
@article{e8001683f9fa4023bd8ac00b06f7d377,
title = "Treatment of mild headache in disabled migraine sufferers: Results of the spectrum study",
abstract = "Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78{\%} versus 0{\%}, P=.02), but not 2 hours postdose (52{\%} versus 0{\%}, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85{\%} versus 17{\%}) and 2 hours (50{\%} versus 0{\%}) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13{\%} versus 18{\%}). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.",
keywords = "Disability, Migraine, Mild, Spectrum, Sumatriptan",
author = "Cady, {R. K.} and Lipton, {Richard B.} and Hall, {Charles B.} and Stewart, {W. F.} and S. O'Quinn and D. Gutterman",
year = "2000",
doi = "10.1046/j.1526-4610.2000.00144.x",
language = "English (US)",
volume = "40",
pages = "792--797",
journal = "Headache",
issn = "0017-8748",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Treatment of mild headache in disabled migraine sufferers

T2 - Results of the spectrum study

AU - Cady, R. K.

AU - Lipton, Richard B.

AU - Hall, Charles B.

AU - Stewart, W. F.

AU - O'Quinn, S.

AU - Gutterman, D.

PY - 2000

Y1 - 2000

N2 - Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.

AB - Objective. - To evaluate the effectiveness of sumatriptan, 50-mg tablets, versus placebo for early intervention while head pain was mild in patients with disabling migraine. Methods. - A post hoc analysis was performed in a subgroup of patients from a large, randomized, placebo-controlled study of patients with disabling headache who treated while pain was mild. Pain-free response 2 and 4 hours postdose, headache recurrence, and safety were examined. Significance tests were performed only for the first-treated attacks. Results. - Twenty-six patients with disabling headache treated 46 mild and 166 moderate or severe headaches. For the first-treated headaches while pain was mild, pain-free rates were significantly higher for sumatriptan than placebo 4 hours postdose (78% versus 0%, P=.02), but not 2 hours postdose (52% versus 0%, P=.22). Across all headaches treated while pain was mild, pain-free responses were higher for sumatriptan than placebo 4 hours (85% versus 17%) and 2 hours (50% versus 0%) postdose compared with placebo. When the same patients treated headaches while pain was moderate or severe, pain-free rates were lower than that reported for treatment during mild pain. There was a trend toward lower headache recurrence in headaches treated while pain was mild compared with moderate or severe pain (13% versus 18%). No drug-related adverse events were reported in the headaches treated while pain was mild. Conclusions. - Patients with disabling migraine may benefit from early intervention with sumatriptan, 50 mg, while pain is mild.

KW - Disability

KW - Migraine

KW - Mild

KW - Spectrum

KW - Sumatriptan

UR - http://www.scopus.com/inward/record.url?scp=0034527433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034527433&partnerID=8YFLogxK

U2 - 10.1046/j.1526-4610.2000.00144.x

DO - 10.1046/j.1526-4610.2000.00144.x

M3 - Article

C2 - 11135022

AN - SCOPUS:0034527433

VL - 40

SP - 792

EP - 797

JO - Headache

JF - Headache

SN - 0017-8748

IS - 10

ER -